Clinical Outcomes in Patients Needing Peripheral ECMO or Impella Circulatory Support Devices

What this Trial Is About

Researchers are collecting detailed clinical and procedural data from patients who receive extracorporeal membrane oxygenation (ECMO) or Impella device implantation to support heart function. This observational study includes all eligible patients undergoing these treatments at participating sites to assess their clinical outcomes over time. The use of these devices is based on the treating physician's decision and is independent of the study. The study includes all patients receiving either a peripheral cannulated veno-arterial ECMO or microaxial flow pump devices like Impella (2.5, 5, CP, or RP) or newer left ventricular or left atrial ascending aorta devices. Data is collected prospectively from patients who have provided informed consent or, if unable, consent is obtained from relatives or waived by an ethics committee. The study follows patients to evaluate their outcomes after device implantation. Participants will be monitored to record clinical events and complications, including death rates at 1 month and 6 months after cardiogenic shock, adverse cardiac and cerebrovascular events, vascular complications, bleeding issues, and need for vascular surgery. The time of device implantation and duration of mechanical circulatory support are also tracked. Functional assessments such as the New York Heart Association classification and modified Rankin scale are included. This data collection continues until August 2034, aiming to improve understanding of outcomes after these circulatory support therapies.

CARDSUP - SWISS Circulatory Support Registry